BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22572013)

  • 1. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
    Guo K; Cai L; Zhang Y; Zhu JF; Rong TH; Lin P; Hao CL; Wang WP; Li Z; Zhang LJ
    Chin J Cancer; 2012 Aug; 31(8):399-408. PubMed ID: 22572013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
    J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus.
    Takeda FR; Tustumi F; de Almeida Obregon C; Yogolare GG; Navarro YP; Segatelli V; Sallum RAA; Junior UR; Cecconello I
    Ann Surg Oncol; 2020 Apr; 27(4):1241-1247. PubMed ID: 31664618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
    Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
    World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
    Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
    J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
    Valencia Julve J; Alonso Orduña V; Escó Barón R; López-Mata M; Méndez Villamón A
    Clin Transl Oncol; 2006 Jan; 8(1):22-30. PubMed ID: 16632436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
    Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
    Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas.
    Langer R; Ott K; Feith M; Lordick F; Siewert JR; Becker K
    Mod Pathol; 2009 Dec; 22(12):1555-63. PubMed ID: 19801967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery.
    Mehta SP; Jose P; Mirza A; Pritchard SA; Hayden JD; Grabsch HI
    Dis Esophagus; 2013; 26(2):182-8. PubMed ID: 22591020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
    Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
    Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.